Furthermore, other experiments have shown that the stent-eluting agent sirolimus can increase protein kinase C-mediated phosphorylation of endothelial nitric oxide synthase, leading to reduced production of vascular nitric oxide (NO) and endothelial dysfunction (52). The gene discussed is NOS3; the disease is endothelial dysfunction.